Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Trevi Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Trevi Therapeutics, Inc.’s stock price such as:

• Trevi Therapeutics, Inc.’s current stock price and volume
• Why Trevi Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TRVI from analysts
• TRVI’s stock price momentum as measured by its relative strength

About Trevi Therapeutics, Inc. (TRVI)

Before we jump into Trevi Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Want to learn more about Trevi Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Trevi Therapeutics, Inc..

Trevi Therapeutics, Inc.’s Stock Price as of Market Close

As of July 17, 2026, 12:46 PM, CST, Trevi Therapeutics, Inc.’s stock price was $18.980.

Trevi Therapeutics, Inc. is up 9.33% from its previous closing price of $17.360.

During the last market session, Trevi Therapeutics, Inc.’s stock traded between $17.230 and $20.220. Currently, there are approximately 145.59 million shares outstanding for Trevi Therapeutics, Inc..

Trevi Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Trevi Therapeutics, Inc. Stock Price History

Trevi Therapeutics, Inc.’s (TRVI) price is currently up 1.77% so far this month.

During the month of July, Trevi Therapeutics, Inc.’s stock price has reached a high of $20.220 and a low of $16.240.

Over the last year, Trevi Therapeutics, Inc. has hit prices as high as $20.150 and as low as $6.550. Year to date, Trevi Therapeutics, Inc.’s stock is up 51.6%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Trevi Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 16, 2026, there were 0 analysts who downgraded Trevi Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Trevi Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Trevi Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Trevi Therapeutics, Inc. (TRVI) by visiting AAII Stock Evaluator.

Relative Price Strength of Trevi Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 16, 2026, Trevi Therapeutics, Inc. has a weighted four-quarter relative price strength of 19.80%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Trevi Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Trevi Therapeutics, Inc. Stock Price: Bottom Line

As of July 17, 2026, Trevi Therapeutics, Inc.’s stock price is $18.980, which is up 9.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Trevi Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.